513. Deputy Ken O'Flynn asked the Minister for Health whether one-way or probabilistic sensitivity analyses were conducted as part of the pharmacoeconomic evaluations of tirzepatide and semaglutide; and if so, the key variables identified as having the greatest impact on cost-effectiveness outcomes. [15814/26]

Summary

513. Deputy Ken O'Flynn asked the Minister for Health whether one-way or probabilistic sensitivity analyses were conducted as part of the pharmacoeconomic evaluations of tirzepatide and semaglutide; and if so, the key variables identified as having the greatest impact on cost-effectiveness outcomes. [15814/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 26 February 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.